Hyperphosphatemia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026

 

Hyperphosphatemia Drugs

Hyperphosphatemia is a condition caused as a result of higher level of phosphate or phosphorous in the blood. Phosphate is a chemical present in body and contain mineral called phosphorous. Phosphorus mineral is vital for the development of teeth and bones and also convert food into energy for body. Phosphate is especially present in one's teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for the management of phosphate level in the body. However, various complications/diseases results into impairment of kidney, that leads to chronically higher level of phosphate in blood.

Hyperphosphatemia is extremely common in people who have chronic kidney disease more frequently in people who have end-stage kidney disease. Some other possible factors behind hyperphosphatemia includes diabetic ketoacidosis, uncontrolled diabetes, high vitamin D levels, and low parathyroid hormone levels.

Hyperphosphatemia Drugs Market Drivers

Increasing launches and approval of novel drugs in key regions are anticipated to fuel the global hyperphosphatemia drugs market growth in near future. As an example, in 2016, Astellas Pharma Inc. received marketing approval because of its Kiklin Granules 86.2%, indicated for treating hyperphosphatemia in patients with chronic kidney disease in Japan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from European Commission for new drug Fexeric (R) (ferric citrate coordination complex), indicated for treating hyperphosphatemia in adults with chronic kidney disease.

In 2014, Keryx Biopharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for drug Ferric Citrate (formerly referred to as Zerenex), a brand new, oral iron-based treatment for dialysis patients with hyperphosphatemia. In 2014, Keryx Biopharmaceuticals, Inc. launched its new drug Auryxia (ferric citrate) tablets. Auryxia is definitely an absorbable iron-based phosphate binder indicated for treating hyperphosphatemia in chronic kidney disease

Strategic merger and acquisition by key players in the market can be expected to make a lucrative environment for the Hyperphosphatemia Drugs Market growth. As an example, in 2013, OPKO Health, Inc. acquired Canada-based Cytochroma Inc., with this strategic acquisition OPKO Health, Inc. has expanded its portfolio with Cytochroma Inc.' s Alpharen, a non-absorbed phosphate binder to take care of hyperphosphatemia in dialysis patients. 

More Relevant Content@ https://www.coherentmarketinsights.com/ongoing-insight/monobody-based-therapeutic-drugs-market-43

Comments

Post a Comment

Popular posts from this blog

Security Robot Market is Estimated To Witness High Growth Owing To Increasing Demand for Enhanced Surveillance

Image
Security Robot Market The Security Robot Market is estimated to be valued at US$ 11.8 billion in 2022 and is expected to exhibit a CAGR of 12.87% over the forecast period of 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The Security Robot Market encompasses advanced robotic technologies that are specifically designed and developed to enhance security and surveillance operations. These robots are equipped with features such as video surveillance, thermal imaging, facial recognition, and intrusion detection, among others. They are extensively used by security agencies and organizations across various sectors, including residential, commercial, industrial, and government, to enhance safety, reduce human intervention, and streamline security operations. Security robots offer real-time monitoring, remote control, and high accuracy, making them an ideal choice for surveillance in sensitive areas and remote locations. Market Dynamics:
Read more

The Ever-Evolving Landscape of the Scottish Whisky Market during the Forecast Period 2019-2027

Image
  Scottish Whisky Market The Scottish Whisky Market is a captivating landscape that has been evolving and transforming over the years. It is a world of tradition, craftsmanship, and heritage, where every drop of whisky tells a story. The history of Scottish whisky traces back centuries, with the earliest records dating back to the 15th century. Whisky production initially started in monasteries, where monks distilled spirits for medicinal purposes. Over time, whisky production moved from monastic settings to farms and then to commercial distilleries. This transition marked the beginning of an industry that would become synonymous with Scotland. Scottish Whisky Market Was Valued At US$ 4.97 Bn In 2018, And It Is Expected To Reach US$ 7.89 Bn By The End Of 2027, Exhibiting A CAGR Of 5.3% During The Forecast Period (2019 To 2027). One of the defining characteristics of the Scottish Whisky Market is its adherence to traditional production methods. Scotch whisky is made from malted b
Read more

Monochloroacetic Acid (MCAA) Market Is Estimated To Witness High Growth Owing To Increasing Demand for Surfactants and Herbicides

Image
Monochloroacetic Acid (MCAA) Market The Monochloroacetic Acid (MCAA) Market is estimated to be valued at USD 676.52 Million in 2022 and is expected to exhibit a CAGR of 7.03% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The Monochloroacetic Acid (MCAA) Market is driven by the increasing demand for surfactants and herbicides in several industries such as agriculture, pharmaceuticals, textiles, and personal care. MCAA is extensively used in the production of surfactants, herbicides, and carboxymethyl cellulose (CMC), which are essential in various applications. These applications include detergents, agrochemicals, pharmaceuticals, dyes, and cosmetics, among others. The versatile properties of MCAA, such as its ability to act as a raw material in the production of herbicides and surfactants, make it highly desirable in the market. Market Dynamics: The Monochloroacetic Acid (MCAA) Market is driven by two k
Read more